KPTI vs ADMA vs FOLD vs HALO

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus 0. 6% for Karyopharm Therapeutics Inc. (KPTI). ADMA Biologics, Inc. (ADMA) offers the better valuation at 14. 1x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Karyopharm Therapeutics Inc. (KPTI) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ADMA Biologics, Inc.

(ADMA) is the cheapest at 14. 1x versus Halozyme Therapeutics, Inc. at 25. 5x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +386. 8%, compared to -93. 0% for Karyopharm Therapeutics Inc. (KPTI). Over 10 years, the gap is even starker: HALO returned +570. 7% versus KPTI's -92. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Karyopharm Therapeutics Inc. 's 1. 55β — meaning KPTI is approximately 177% more volatile than HALO relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 17% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus 0. 6% for Karyopharm Therapeutics Inc. (KPTI). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 51. 2% year-over-year, compared to -90. 5% for Karyopharm Therapeutics Inc.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus -134. 2% for Karyopharm Therapeutics Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -62. 1% for KPTI. At the gross margin level — before operating expenses — KPTI leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 1x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 32. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 165. 6% to $22. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Karyopharm Therapeutics Inc. (KPTI) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, KPTI: -92. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KPTI is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; HALO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.